Anti-NKG2A antibodies and uses thereof

Patent metadata

Field	Value
Publication number	US-9683041-B2
Application number	US-201414548327-A
Country	US
Kind code	B2
Filing date	Nov 20, 2014
Priority date	Jun 30, 2006
Publication date	Jun 20, 2017
Grant date	Jun 20, 2017

Abstract

Described herein are anti-NKG2A antibodies suitable for human therapy, including humanized versions of murine anti-NKG2A antibody Z270, as well as related methods and materials for producing and using such antibodies. Exemplary complementarity-determining regions (CDRs) sequences and sites for optional amino acid back-substitutions in framework region (FR) and/or CDRs of such antibodies are also described.

First claim

We claim:

1. A method of treating a human patient suffering from a cancer, the method comprising administering to the human patient a non-depleting antibody or antigen binding fragment thereof that specifically binds NKG2A or a pharmaceutical composition comprising said antibody or antigen binding fragment, wherein the antibody comprises antigen-binding residues from the complementarity-determining regions (CDRs) of murine antibody Z270 and human acceptor framework sequences, wherein said antibody comprises a VL domain that is at least 90% identical to SEQ ID NO: 4 and a VH domain that is at least 90% identical to SEQ ID NO: 5, and wherein said antibody comprises CDR-H1 corresponding to residues 31-35 of SEQ ID NO: 5, CDR-H2 corresponding to residues 50-60 of SEQ ID NO: 5, CDR-H3 corresponding to residues 99-114 of SEQ ID NO: 5, CDR-L1 corresponding to residues 24-34 of SEQ ID NO: 4, CDR-L2 corresponding to residues 50-56 of SEQ ID NO: 4 and CDR-L3 corresponding to residues 89-97 of SEQ ID NO: 4.

2. The method of claim 1 , wherein:
the amino acid at position 5 of the VH domain is V or Q;
the amino acid at position 70 of the VH domain is M or L;
the amino acid at position 72 of the VH domain is T or V;
the amino acid at position 74 of the VH domain is T or K; or
the amino acid at position 76 of the VH domain is T or S.

3. The method of claim 1 , wherein the VH domain human acceptor framework sequences of said antibody are free of any back-mutations.

4. The method of claim 1 , wherein the VH domain of said antibody comprises the sequence of SEQ ID NO: 5.

5. The method of claim 1 , wherein the VL domain of said antibody comprises SEQ ID NO: 4.

6. The method of claim 1 , wherein the antibody is an IgG4 antibody.

7. The method of claim 1 , wherein said antibody is an antigen binding fragment or a multispecific antibody.

8. The method according to claim 1 , wherein said cancer is selected from the group consisting of bladder cancer, breast cancer, colon cancer, kidney cancer, liver cancer, lung cancer, ovary cancer, prostate cancer, pancreatic cancer, stomach cancer, cervical cancer, thyroid cancer, skin cancer, leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma, Burkitt's lymphoma, multiple myeloma, acute and chronic myelogenous leukemias, promyelocytic leukemia, myelodysplastic syndrome, fibrosarcoma, rhabdomyosarcoma, melanoma, seminoma, neuroblastoma, astrocytoma, neuroblastoma, glioma, schwannomas, osteosarcoma, xeroderma pigmentosum, keratoacanthoma, thyroid follicular cancer and teratocarcinoma.

9. The method of claim 1 , wherein the antibody is a humanized antibody that:
a) specifically binds to NKG2A,
b) does not specifically bind to an Fc receptor, and
c) when bound to NKG2A on a human NK cell, causes said NK cell to lyse a target human cell bearing HLA-E on the target cell surface, when said target cell comes into contact with said NK cell.

10. The method of claim 1 , wherein the antibody is Fab or F(ab')2 fragment.

11. The method of claim 1 , wherein the antibody comprises a modified Fc portion, which is modified to minimize or eliminate binding to Fc receptors.

12. The method of claim 1 , wherein said cancer is cervical cancer.

13. The method of claim 1 , wherein said cancer is leukemia or lymphoma.

14. The method of claim 1 , wherein said cancer cells express HLA-E.

Assignees

• Novo Nordisk As

Inventors

• Spee Petrus Johannes Louis
• Padkaer Soeren Berg

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P31/12

  Antivirals · CPC title